Effects of teriparatide on hip and upper limb fractures in patients with osteoporosis: A systematic review and meta-analysis.
Adolfo Diez-Perez,Fernando Marin,Erik Fink Eriksen,David L. Kendler,John H. Krege,Miguel Delgado-Rodríguez +5 more
TLDR
A systematic review and meta-analysis provides evidence of efficacy of teriparatide in reducing hip fractures by 56% in patients with osteoporosis.About:
This article is published in Bone.The article was published on 2019-03-01 and is currently open access. It has received 68 citations till now. The article focuses on the topics: Hip fracture & Teriparatide.read more
Citations
More filters
Journal ArticleDOI
Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures
J. A. Kanis,J. A. Kanis,Nicholas C. Harvey,Eugene V. McCloskey,Eugene V. McCloskey,Olivier Bruyère,Nicola Veronese,Mattias Lorentzon,Mattias Lorentzon,Mattias Lorentzon,Cyrus Cooper,Cyrus Cooper,René Rizzoli,Gemma Adib,Nasser M. Al-Daghri,C. Campusano,Manju Chandran,Bess Dawson-Hughes,Kassim Javaid,F. Jiwa,Helena Johansson,Helena Johansson,Joon Kiong Lee,Enwu Liu,Demetrio Messina,O. Mkinsi,Daniel Pinto,Daniel Pinto,Daniel Prieto-Alhambra,Daniel Prieto-Alhambra,Kenneth G. Saag,Weibo Xia,L. Zakraoui,Jean-Yves Reginster,Jean-Yves Reginster +34 more
TL;DR: Guidance is provided in an international setting on the assessment and specific treatment of postmenopausal women at low, high and very high risk of fragility fractures as mentioned in this paper, taking additional account of further categorisation of increased risk of fracture.
Journal ArticleDOI
Secondary Fracture Prevention: Consensus Clinical Recommendations from a Multistakeholder Coalition
Robert B. Conley,Gemma Adib,Robert A. Adler,Kristina Åkesson,Ivy M. Alexander,Kelly C. Amenta,Robert D. Blank,Robert D. Blank,William Timothy Brox,Emily E. Carmody,Karen Chapman-Novakofski,Bart L. Clarke,Kathleen M. Cody,Cyrus Cooper,Carolyn J. Crandall,Douglas R. Dirschl,Thomas J. Eagen,Ann L. Elderkin,Masaki Fujita,Susan L. Greenspan,P. Halbout,Marc C. Hochberg,Muhammad Javaid,Kyle J. Jeray,Ann E. Kearns,Toby King,Thomas F. Koinis,Jennifer Scott Koontz,Martin Kužma,Carleen Lindsey,Mattias Lorentzon,Mattias Lorentzon,Mattias Lorentzon,George P. Lyritis,Laura Boehnke Michaud,Armando Miciano,Suzanne N Morin,Nadia Mujahid,Nicola Napoli,Nicola Napoli,Thomas P. Olenginski,J. Edward Puzas,Stavroula Rizou,Clifford J. Rosen,Clifford J. Rosen,Kenneth G. Saag,Elizabeth Thompson,Laura L. Tosi,Howard Tracer,Sundeep Khosla,Douglas P. Kiel +50 more
TL;DR: Clinical recommendations for the optimal prevention of secondary fracture among people aged 65 years and older with a hip or vertebral fracture and patients should be strongly encouraged to avoid tobacco, consume alcohol in moderation at most, and engage in regular exercise and fall prevention strategies.
Journal ArticleDOI
Drug therapy for osteoporosis in older adults
TL;DR: For example, the authors showed that anabolic agents have greater anti-fracture efficacy and produce larger increases in bone density than anti-resorptive drugs. But, the effects of anabolic drugs are transient and the optimal strategy for cycling anabolics, antiresorptives, and off-treatment periods remains to be determined.
Journal ArticleDOI
Drug therapy for osteoporosis in older adults
Ian R. Reid,Emma O. Billington +1 more
TL;DR: Head-to-head studies suggest that anabolic agents have greater anti-fracture efficacy and produce larger increases in bone density than anti-resorptive drugs.
Journal ArticleDOI
UK clinical guideline for the prevention and treatment of osteoporosis
Celia L Gregson,David J. Armstrong,JP Bowden,Cyrus Cooper,J. Edwards,Neil Gittoes,Nicholas C. Harvey,John A. Kanis,Sarah Leyland,Rebecca Low,Eugene V. McCloskey,K Moss,Jane E Parker,Zoe Paskins,Kenneth E. S. Poole,David M. Reid,Mike Stone,J Thomson,Nic Vine,Juliet E. Compston +19 more
TL;DR: The UK National Osteoporosis Guideline Group (NOGG) as discussed by the authors has revised the UK guideline for the assessment and management of osteopsorosis and the prevention of fragility fractures in postmenopausal women, and men age 50 years and older.
References
More filters
Journal ArticleDOI
Bias in meta-analysis detected by a simple, graphical test
TL;DR: Funnel plots, plots of the trials' effect estimates against sample size, are skewed and asymmetrical in the presence of publication bias and other biases Funnel plot asymmetry, measured by regression analysis, predicts discordance of results when meta-analyses are compared with single large trials.
Journal ArticleDOI
The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials
Julian P T Higgins,Douglas G. Altman,Peter C Gøtzsche,Peter Jüni,David Moher,Andrew D Oxman,Jelena Savović,Kenneth F. Schulz,Laura Weeks,Jonathan A C Sterne +9 more
TL;DR: The Cochrane Collaboration’s tool for assessing risk of bias aims to make the process clearer and more accurate.
Journal ArticleDOI
Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation.
Larissa Shamseer,David Moher,Mike Clarke,Davina Ghersi,Alessandro Liberati,Mark Petticrew,Paul G. Shekelle,Lesley A. Stewart +7 more
TL;DR: The PRISMA-P checklist as mentioned in this paper provides 17 items considered to be essential and minimum components of a systematic review or meta-analysis protocol, as well as a model example from an existing published protocol.
Journal ArticleDOI
Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.
Robert M. Neer,Claude D. Arnaud,Jose R. Zanchetta,Richard L. Prince,Gregory A Gaich,Jean-Yves Reginster,Anthony B. Hodsman,Erik Fink Eriksen,Sophia Ish-Shalom,Harry K. Genant,Ouhong Wang,Bruce H. Mitlak +11 more
TL;DR: Treatment of postmenopausal osteoporosis with parathyroid hormone decreases the risk of vertebral and nonvertebral fractures; increases vertebral, femoral, and total-body bone mineral density; and is well tolerated.
Journal ArticleDOI
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
Dennis M. Black,Steven R. Cummings,David B. Karpf,Jane A. Cauley,Desmond E. Thompson,Michael C. Nevitt,Douglas C. Bauer,Harry K. Genant,William L. Haskell,Robert Marcus,Susan M. Ott,James C. Torner,Sara A. Quandt,Theodore F. Reiss,Kristine E. Ensrud +14 more
TL;DR: Among women with low bone mass and existing vertebral fractures, alendronate is well tolerated and substantially reduces the frequency of morphometric and clinical vertebra fractures, as well as other clinical fractures.